North America Biologics Market to 2031 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. North America Biologics Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. North America Biologics Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Preference for Outsourcing Manufacturing Operations

5.2 Market Opportunities

5.2.1 Gene and Cell Therapy Advancements in Biologics

5.3 Future Trends

5.3.1 Strategic Initiatives by Companies

5.4 Impact of Drivers and Restraints

6. North America Biologics Market Regional Analysis

6.1 North America Biologics Market Overview

6.2 North America Biologics Market Revenue 2021-2031 (US$ Million)

6.3 North America Biologics Market Forecast Analysis

7. North America Biologics Market Analysis – by Product

7.1 Monoclonal Antibodies

7.1.1 Overview
7.1.2 Monoclonal Antibodies: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Vaccine

7.2.1 Overview
7.2.2 Vaccine: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Recombinant Hormones/Proteins

7.3.1 Overview
7.3.2 Recombinant Hormones/Proteins: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Cell and Gene Therapy

7.4.1 Overview
7.4.2 Cell and Gene Therapy: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Others

7.5.1 Overview
7.5.2 Others: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Biologics Market Analysis – by Application

8.1 Cancer

8.1.1 Overview
8.1.2 Cancer: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview
8.2.2 Infectious Diseases: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

8.3 Autoimmune Diseases

8.3.1 Overview
8.3.2 Autoimmune Diseases: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

8.4 Others

8.4.1 Overview
8.4.2 Others: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

9. North America Biologics Market Analysis – by Source

9.1 Mammalian and Microbial

9.1.1 Overview
9.1.2 Others: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

10. North America Biologics Market – North America Analysis

10.1 North America

10.1.1 North America Biologics Market Breakdown, by Key Country, 2025 and 2031 (%)
10.1.1.1 North America Biologics Market – Revenue and Forecast Analysis – by Country
10.1.1.1 US: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.1.1 US: North America Biologics Market Breakdown, by Product
10.1.1.1.2 US: North America Biologics Market Breakdown, by Application
10.1.1.1.3 US: North America Biologics Market Breakdown, by Source

10.1.1.2 Canada: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.2.1 Canada: North America Biologics Market Breakdown, by Product
10.1.1.2.2 Canada: North America Biologics Market Breakdown, by Application
10.1.1.2.3 Canada: North America Biologics Market Breakdown, by Source

10.1.1.3 Mexico: North America Biologics Market – Revenue and Forecast to 2031 (US$ Million)

10.1.1.3.1 Mexico: North America Biologics Market Breakdown, by Product
10.1.1.3.2 Mexico: North America Biologics Market Breakdown, by Application
10.1.1.3.3 Mexico: North America Biologics Market Breakdown, by Source

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. North America Biologics Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 AbbVie Inc

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Pfizer Inc

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 Samsung Biologics Co Ltd

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 ADMA Biologics, Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Wuxi Biologics Inc

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Catalent Inc

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 AGC Biologics AS

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 AstraZeneca Plc

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Amgen Inc

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Nitto Avecia

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

13.11 Quality Assistance s.a.

13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments

14. Appendix

14.1 About Business Market Insights